about
Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosisA dynamic analysis of tuberculosis dissemination to improve control and surveillanceCombined immunization using DNA-Sm14 and DNA-Hsp65 increases CD8+ memory T cells, reduces chronic pathology and decreases egg viability during Schistosoma mansoni infectionEndocytosis of DNA-Hsp65 alters the pH of the late endosome/lysosome and interferes with antigen presentation.Cytotoxic T cells and mycobacteria.Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes.Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A.Antibody response from whole-cell pertussis vaccine immunized Brazilian children against different strains of Bordetella pertussis.Mycobacterium tuberculosis expressing phospholipase C subverts PGE2 synthesis and induces necrosis in alveolar macrophages.Helminth coinfection does not affect therapeutic effect of a DNA vaccine in mice harboring tuberculosis.Identification and characterization of murine cytotoxic T cells that kill Mycobacterium tuberculosisLow-dose plasmid DNA treatment increases plasma vasopressin and regulates blood pressure in experimental endotoxemia.Leukotrienes are involved in leukocyte recruitment induced by live Histoplasma capsulatum or by the beta-glucan present in their cell wallExposure to high endotoxin concentration increases wheezing prevalence among laboratory animal workers: a cross-sectional study.New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro.P2×7 purinergic signaling in dilated cardiomyopathy induced by auto-immunity against muscarinic M2 receptors: autoantibody levels, heart functionality and cytokine expression.IL-5 drives eosinophils from bone marrow to blood and tissues in a guinea-pig model of visceral larva migrans syndromeImmunotherapy of tuberculosis with Mycobacterium leprae Hsp65 as a DNA vaccine triggers cross-reactive antibodies against mammalian Hsp60 but not pathological autoimmunity.BCG and BCG/DNAhsp65 vaccinations promote protective effects without deleterious consequences for experimental autoimmune encephalomyelitis.Antigen-presenting cells transfected with Hsp65 messenger RNA fail to treat experimental tuberculosis.Mycobacterium tuberculosis culture filtrate proteins plus CpG Oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion.pVAXhsp65 Vaccination Primes for High IL-10 Production and Decreases Experimental Encephalomyelitis Severity.The impact of transcriptomics on the fight against tuberculosis: focus on biomarkers, BCG vaccination, and immunotherapy.Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis.Role of trehalose dimycolate in recruitment of cells and modulation of production of cytokines and NO in tuberculosis.Structure activity relationship, acute toxicity and cytotoxicity of antimycobacterial neolignan analogues.Mycobacterial Hsp65 antigen upregulates the cellular immune response of healthy individuals compared with tuberculosis patients.MicroRNA expression signatures in lungs of mice infected with Mycobacterium tuberculosis.Towards a DNA vaccine against tuberculosis.Blockade of endogenous leukotrienes exacerbates pulmonary histoplasmosis.Plasma eicosanoid profiles determined by high-performance liquid chromatography coupled with tandem mass spectrometry in stimulated peripheral blood from healthy individuals and sickle cell anemia patients in treatment.Synergy of chemotherapy and immunotherapy revealed by a genome-scale analysis of murine tuberculosis.Genetic vaccination against tuberculosis.Control of experimental pulmonary tuberculosis depends more on immunostimulatory leukotrienes than on the absence of immunosuppressive prostaglandins.Modulation of angiogenic factor VEGF by DNA-hsp65 vaccination in a murine CNS tuberculosis model.Cytoplasmic and extracellular expression of pharmaceutical-grade mycobacterial 65-kDa heat shock protein in Lactococcus lactis.Nanobiotechnological approaches to delivery of DNA vaccine against fungal infection.TLR2-dependent mast cell activation contributes to the control of Mycobacterium tuberculosis infection.Experimental tuberculosis: designing a better model to test vaccines against tuberculosis.Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice.
P50
Q21256673-A74D2CE7-B641-4AE3-8E60-4E2E94AE5AABQ27316245-EFDE5F9A-9C14-4E86-8E01-AD15ACF30428Q30578697-8A27D762-1E41-46C4-ADEC-3AA3DEBE14C4Q33300327-16DCFB7C-ACD3-49FB-9347-919C39779A9BQ33335515-CAD1327E-4BC4-4E3F-9EF7-E1EC678EED1DQ33353872-BCEAD60B-14E2-4EB2-8AAA-1F23C1241E67Q33525571-43AA0C82-D080-49E3-A73E-F1760A8BFD6CQ33749729-01BF0D8D-00BA-4962-866D-295AFF08D58FQ33756527-F0C37E3E-29F3-4344-ABA8-BC6FDBDCE5A2Q33900309-0D6C03A1-2D99-4142-97F9-78B0B10BF84FQ34004633-11BC18E6-40BA-4310-BC61-7BE20E15863BQ34471220-DBEFBE81-DCB3-4E33-BBC8-E5700D002188Q35041719-5ECF72AF-9A0F-4501-A0B2-1475A487EDBCQ36011245-776DBB4C-A98B-4DDD-9502-288C174B81C8Q36013722-A85252DA-C75E-425A-9884-50BCD90A9FC3Q36305471-C5940250-25A3-47A0-AC5D-26A410B394DDQ36628083-61D4A442-1E7D-4578-9792-6158520228AFQ36977794-EC5807CB-A1E7-49E1-89B0-36C7E1A13625Q37316205-A728EE80-5989-4506-B85B-12C71DD15A1EQ37371021-22BFC120-2965-4FC4-B4E9-FD93333DD0EFQ37451207-192B438F-5B77-4DB4-B3E5-C7126882D558Q37683473-066B9563-218B-478C-AA2F-50C63894EA31Q37825430-C7029256-17F0-4255-A25C-61F70B5A82A8Q39294350-6FE9D25F-987F-435E-9ECE-0BD56E05BAB3Q39521774-4CC76898-1ED2-48CB-825D-766B41EBF28CQ39531716-401C14BF-5F3E-4A73-8653-49EC076E5A95Q40383030-2DBA515A-DA93-473C-9BE5-BF581A1707EDQ40444262-22D5AB6F-4A1D-472E-B926-AF4D405E6647Q40605760-B7F9A8C6-277F-4F2E-B05D-0CBD9500DAB4Q40633832-22DD3542-5E1F-4741-AE51-00750F6CFE2CQ40758763-FEDBAA95-BEE6-4AF3-A66A-6EB2F3E5D68DQ41480039-DF07A52D-C16B-41E0-A357-691064063A00Q41666687-89B96A94-59CF-4EC1-8B4C-D888E1FD6038Q41774199-88B8B1BD-B2E6-441B-849E-D3A9DDC12D41Q43501419-B31A4548-A5BB-4DE7-BDDC-2A18665AB071Q43807117-9384ED3D-5B91-4F6F-9143-545FF0ECED33Q43905915-14915B14-956D-4577-9A36-EFC03280988CQ44258712-F6C54975-C2A9-4636-BD43-0246A24520E1Q44415807-6EA05EEE-B307-465C-BE56-200F7743D6C7Q44531712-9DF48254-6E77-42D1-882B-E79951842BC2
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Célio L Silva
@ast
Célio L Silva
@en
Célio L Silva
@es
Célio L Silva
@nl
Célio L Silva
@sl
type
label
Célio L Silva
@ast
Célio L Silva
@en
Célio L Silva
@es
Célio L Silva
@nl
Célio L Silva
@sl
prefLabel
Célio L Silva
@ast
Célio L Silva
@en
Célio L Silva
@es
Célio L Silva
@nl
Célio L Silva
@sl
P106
P31
P496
0000-0002-0043-4568